References
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
- Marrone G, Vaccaro FG, Biolato M, et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci. 2017;21:122–134.
- Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62:481–492.
- WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Oral Contraceptives. A randomized double-blind study of the effects of two low-dose combined oral contraceptives on biochemical aspects. Report from a seven-centred study. Contraception. 1985;32:223–236.
- De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24:1187–1195.
- Elouni B, Ben Salem C, Zamy M, et al. Cytolytic hepatitis possibly related to levonorgestrel/ethinylestradiol oral contraceptive use: 2 case reports. Ann Pharmacother. 2010;44:2035–2037.
- Loulergue P, Coriat R, Mir O. Recurrent transaminitis induced by oral contraceptives during HIV infection. Ann Pharmacother. 2015;49:258–259.
- Hannaford PC, Kay CR, Vessey MP, et al. Combined oral contraceptives and liver disease. Contraception. 1997;55:145–151.
- Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185–194.
- Margonis GA, Ejaz A, Spolverato G, et al. Benign solid tumors of the liver: management in the modern era. J Gastrointest Surg. 2015;19:1157–1168.